Authors: Martha Powell, Future Science Group
A Phase II trial on tuberculosis (TB) vaccines has suggested the potential for new Bacille Calmette–Guerin (BCG) revaccination strategies in addition to hope for subunit vaccines against the disease, according to results presented at the 5th Global Forum on TB Vaccines (20–23 February, New Delhi, India).
This trial, which took place in the Western Cape Province of South Africa, represents the first prevention-of-infection trial for TB. Currently BCG is the only licensed vaccine for TB and past studies have indicated that primary BCG vaccination may only offer partial protection, suggesting revaccination could provide additional benefits. However, this hypothesis has not been tested in a randomized, placebo-controlled trial, prior to this one.